Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, SBRT, and GP Chemotherapy for Hilar Cholangiocarcinoma
NCT07030140Phase 2Recruiting
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in hilar cholangiocarcinoma (HC). Started Jul 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
hilar cholangiocarcinoma (HC)
Beyond the preview
Go deeper on NCT07030140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030140.